34080-08-5
Chemical Structure
(20S)-Protopanaxatriol
Synonym(s): 20(S)-APPT; g-PPT
- CAS No.: 34080-08-5
- Formula:C30H52O4
- Molecular Weight:476.73
IUPAC Name: (3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-((S)-2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,6,12-triol
InChIKey: SHCBCKBYTHZQGZ-CJPZEJHVSA-N
SMILES: C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O)C)(C[C@H](O)[C@@]2([H])C3(C)C)[C@]4([C@@]1([H])[C@]([C@@](C)(O)CC/C=C(C)/C)([H])CC4)C
Biological Activity: (20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER), and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(20S)-Protopanaxatriol | 99.93% | (20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER), and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(20S)-Protopanaxatriol (Standard) | ≥98% | (20S)-Protopanaxatriol (Standard) is the analytical standard of (20S)-Protopanaxatriol. This product is intended for research and analytical applications. (20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER), and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Leung KW, et al. Protopanaxadiol and protopanaxatriol bind to glucocorticoid and oestrogen receptors in endothelial cells. Br J Pharmacol. 2009 Feb;156(4):626-37. [Content Brief]
- [2]. Oh GS, et al. 20(S)-protopanaxatriol inhibits liver X receptor α-mediated expression of lipogenic genes in hepatocytes. J Pharmacol Sci. 2015 Jun;128(2):71-7. [Content Brief]
- [3]. Huang Q, et al. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):129. Published 2019 Mar 15. [Content Brief]
